How do we reset the faulty immune system? One solution is HSCT: hematopoietic stem cell transplantation. The Relapse After HSCT² Workshop is held to dive deep into this important cancer treatment specialty treatment. Each workshop builds on the research, experience and evidence found since the last meeting, and includes experts talking about the latest in HSCT.
Join us live in 2021 to continue the information sharing developed at previous workshops and use it to build out ongoing developments in this vital specialty. Attend to learn about the latest breakthroughs and treatment advances in HSCT so we can all better serve our patients and the medical community overall. Plan your trip October 7-9, 2021 at the Sheraton New York Times Square in New York City.
Now Accepting Abstract Submissions!
Attendees are invited to submit an abstract for poster presentation and/or oral presentation during the workshop. Abstracts may pertain to any and all areas related to the biology, prevention and treatment of relapse after hematopoietic stem cell transplantation.
Submissions must be made electronically through the online submission page no later than August 15, 2021.
Have a question? Contact us at HSCTconference@mocandco.com.
Attendees are invited to submit an abstract for poster presentation and/or oral presentation during the workshop. Abstracts may pertain to any and all areas related to the biology, prevention and treatment of relapse after hematopoietic stem cell transplantation.
Submissions must be made electronically through the online submission page no later than August 15, 2021.
Have a question? Contact us at HSCTconference@mocandco.com.
 Nicolaus Kröger, Alan Wayne, Sergio Giralt, Michael Bishop
FIFTH INTERNATIONAL WORKSHOP
Are you a medical or pediatric hematologist-oncologist, a hematopoietic stem and immune cell translational and basic scientist, a hematopathologist, physician-in-training (Fellows/ Residents/Post Docs), advance practice provider, pharmacist, oncology nurse or another associated allied health professional? If so, you should consider joining us on October 7-9, 2021, in New York City. Relapse and disease progression are the leading causes of treatment failure for most hematologic malignancies treated with both allogeneic and autologous hematopoietic stem cell transplantation. During the last 5 years significant advances have been made in our understanding of the biology of relapse such as understanding the role of HLA loss in leukemia recurrence post-transplant. Since our 1st relapse meeting we now have three drugs approved to prevent disease recurrence post autologous transplant, and the role of FLT3 inhibitors and other TKIs to prevent relapse post allogeneic HCT is actively ongoing. Finally, the efficacy of CD 19 CAR T cell therapy for patients with disease relapsing after HCT has been firmly established for ALL and NHL. The Fifth International Workshop on Biology, Prevention and Treatment of Relapse After Hematopoietic Stem Cell Transplantation and Cellular Therapy (HSCT²) will bring together the leaders in the field to update us on these issues as well as novel mechanisms of relapse that have recently been described and discovered. As a Workshop participant, you will benefit from the knowledge of internationally recognized speakers from a multidisciplinary, diverse group comprised of basic and translational scientists and clinical investigators. Tremendous progress in treatment research has been made over the recent past years, and we are eager to share it with you. The Fifth International Workshop on Biology, Prevention and Treatment of Relapse After Hematopoietic Stem Cell Transplantation and Cellular Therapy (HSCT²) will take place at the first-class, Sheraton New York Times Square. The Organizing Committee is working diligently to make this Fifth International Workshop a truly valuable experience for all participants. We look forward to learning alongside you and to welcoming you to the vibrant, captivating city of New York. |
|
